Purification notesThe antibody was affinity purified from rabbit antiserum by affinity chromatography using epitope specific phosphopeptide. The antibody against non phosphopeptide was removed by chromatography using non phosphopeptide corresponding to the phosphorylation site.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500 - 1/1000. Detects a band of approximately 35 kDa (predicted molecular weight: 34 kDa).
FunctionPlays a key role in the control of the eukaryotic cell cycle. It is required in higher cells for entry into S-phase and mitosis. p34 is a component of the kinase complex that phosphorylates the repetitive C-terminus of RNA polymerase II.
Tissue specificityIsoform 2 is found in breast cancer tissues.
Sequence similaritiesBelongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily. Contains 1 protein kinase domain.
FormCDK1 can be located to the Nucleus, cytoplasm and Mithocondria. It's cytoplasmic during interphase and reversibly translocated from cytoplasm to the nucleus when phosphorilated before G2-M transition when associated with cyclin-B1. Accumulates in mitochondria in G2-arrested cells upon DNA-damage.
Cdc 2 antibody
CDK 1 antibody
CELL CYCLE CONTROLLER CDC2 antibody
Cell division control protein 2 antibody
Cell division control protein 2 homolog antibody
Cell division cycle 2 G1 to S and G2 to M antibody
Cell division protein kinase 1 antibody
Cell Divsion Cycle 2 Protein antibody
Cyclin Dependent Kinase 1 antibody
Cyclin-dependent kinase 1 antibody
p34 Cdk1 antibody
p34 protein kinase antibody
Anti-CDK1 (phospho Y15) antibody images
Western blot - Anti-CDK1 (phospho Y15) antibody (ab47594)
References for Anti-CDK1 (phospho Y15) antibody (ab47594)
This product has been referenced in:
Mo Q et al. Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis. Tumour BiolN/A:N/A (2016).
Read more (PubMed: 27629142) »
Chang L et al. Targeting Rad50 sensitizes human nasopharyngeal carcinoma cells to radiotherapy. BMC Cancer16:190 (2016).
Read more (PubMed: 26951044) »